ะŸะฐะป ะ ะฐั…ัƒะป ะšัƒะผะฐั€

๐‘๐š๐ก๐ฎ๐ฅ Kumar ๐๐š๐ฅ
🥼
🥼
ะ ะฐั…ัƒะป ะผะพะถะตั‚ ัั‚ะฐั‚ัŒ ะฒะฐัˆะธะผ ะฝะฐัƒั‡ะฝั‹ะผ ั€ัƒะบะพะฒะพะดะธั‚ะตะปะตะผ
ะ•ัะปะธ ะฒั‹ ั…ะพั‚ะธั‚ะต ั€ะฐะฑะพั‚ะฐั‚ัŒ ะฟะพะด ะตะณะพ/ะตั‘ ั€ัƒะบะพะฒะพะดัั‚ะฒะพะผ, ะฝะฐะฟะธัˆะธั‚ะต ัะพะพะฑั‰ะตะฝะธะต ะธะปะธ ัะฒัะถะธั‚ะตััŒ ั ะฝะธะผ/ะฝะตะน ะฒ ัะพั†ัะตั‚ัั….
ะะตะพะฑั…ะพะดะธะผะพ ะฐะฒั‚ะพั€ะธะทะพะฒะฐั‚ัŒัั.
🤝
🤝
ะ ะฐั…ัƒะป ะธั‰ะตั‚ ะฒะพะทะผะพะถะฝะพัั‚ะธ ะดะปั ะฝะฐัƒั‡ะฝะพะณะพ ัะพั‚ั€ัƒะดะฝะธั‡ะตัั‚ะฒะฐ
ะ•ัะปะธ ะฒั‹ ั…ะพั‚ะธั‚ะต ะฟั€ะพะฒะตัั‚ะธ ั ะฝะธะผ/ะฝะตะน ัะพะฒะผะตัั‚ะฝะพะต ะธััะปะตะดะพะฒะฐะฝะธะต, ะฝะฐะฟะธัˆะธั‚ะต ัะพะพะฑั‰ะตะฝะธะต ะธะปะธ ัะฒัะถะธั‚ะตััŒ ั ะฝะธะผ/ะฝะตะน ะฒ ัะพั†ัะตั‚ัั….
ะะตะพะฑั…ะพะดะธะผะพ ะฐะฒั‚ะพั€ะธะทะพะฒะฐั‚ัŒัั.
ะŸัƒะฑะปะธะบะฐั†ะธะน
36
ะฆะธั‚ะธั€ะพะฒะฐะฝะธะน
96
ะ˜ะฝะดะตะบั ะฅะธั€ัˆะฐ
5

ะž ัะตะฑะต

๐‡๐ž๐ฒ ๐„๐ฏ๐ž๐ซ๐ฒ๐จ๐ง๐ž;

๐–๐š๐ซ๐ฆ ๐ฐ๐ž๐ฅ๐œ๐จ๐ฆ๐ž ๐ญ๐จ ๐ฆ๐ฒ ๐ฉ๐ซ๐จ๐Ÿ๐ข๐ฅ๐ž, Working as "๐€๐ฌ๐ฌ๐ข๐ฌ๐ญ๐š๐ง๐ญ ๐๐ซ๐จ๐Ÿ๐ž๐ฌ๐ฌ๐จ๐ซ", ๐ƒ๐ž๐ฉ๐š๐ซ๐ญ๐ฆ๐ž๐ง๐ญ ๐จ๐Ÿ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ฒ, ๐‰๐š๐ ๐š๐ง๐ง๐š๐ญ๐ก ๐”๐ง๐ข๐ฏ๐ž๐ซ๐ฌ๐ข๐ญ๐ฒ, ๐‚๐ก๐š๐ค๐ฌ๐ฎ, ๐‰๐š๐ข๐ฉ๐ฎ๐ซ, ๐‘๐š๐ฃ๐š๐ฌ๐ญ๐ก๐š๐ง, ๐ˆ๐ง๐๐ข๐š. I had completed my ๐๐š๐œ๐ก๐ž๐ฅ๐จ๐ซ ๐จ๐Ÿ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ฒ (๐. ๐๐ก๐š๐ซ๐ฆ) ๐Ÿ๐ซ๐จ๐ฆ ๐ˆ๐ง๐ฏ๐ž๐ซ๐ญ๐ข๐ฌ ๐”๐ง๐ข๐ฏ๐ž๐ซ๐ฌ๐ข๐ญ๐ฒ, ๐๐š๐ซ๐ž๐ข๐ฅ๐ฅ๐ฒ, ๐”๐. ๐ˆ๐ง๐๐ข๐š. and ๐Œ. ๐๐ก๐š๐ซ๐ฆ (๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ) ๐Ÿ๐ซ๐จ๐ฆ ๐๐ข๐ฆ๐ฌ ๐ˆ๐ง๐ฌ๐ญ๐ข๐ญ๐ฎ๐ญ๐ž ๐จ๐Ÿ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ฒ, ๐๐ข๐ฆ๐ฌ ๐”๐ง๐ข๐ฏ๐ž๐ซ๐ฌ๐ข๐ญ๐ฒ ๐‘๐š๐ฃ๐š๐ฌ๐ญ๐ก๐š๐ง, ๐‰๐š๐ข๐ฉ๐ฎ๐ซ ๐Ÿ‘๐ŸŽ๐Ÿ‘๐Ÿ๐Ÿ๐Ÿ, ๐ˆ๐ง๐๐ข๐š.

๐’๐ฉ๐ž๐œ๐ข๐š๐ฅ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง: "Pharmaceutics".

As a Master's, I had gain lots of knowledge about academics and learning of skills for my profession to increasing my skills. Currently, continues working on review articles, research papers and books writing work etc..

โฆฟ I had published ๐Ÿ’๐Ÿ ๐‘๐ž๐ฏ๐ข๐ž๐ฐ ๐€๐ซ๐ญ๐ข๐œ๐ฅ๐ž๐ฌ (Elsevier*/Bentham/Scopus/PubMed) and ๐Ÿ๐Ÿ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐€๐ซ๐ญ๐ข๐œ๐ฅ๐ž๐ฌ with my acquired knowledge.

โฆฟ I had published and Granted ๐Ÿ๐ŸŽ ๐ˆ๐ง๐๐ข๐š๐ง ๐ƒ๐ž๐ฌ๐ข๐ ๐ง ๐‚๐ž๐ซ๐ญ๐ข๐Ÿ๐ข๐œ๐š๐ญ๐ž, ๐Ÿ๐Ÿ‘ ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐”๐Š Design Patent and ๐Ÿ ๐”๐ญ๐ข๐ฅ๐ข๐ญ๐ฒ ๐๐ฎ๐›๐ฅ๐ข๐œ๐š๐ญ๐ข๐จ๐ง under IPR.

โฆฟ I had attended ๐ŸŽ๐Ÿ” ๐๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐œ๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž, ๐ŸŽ๐Ÿ“ ๐จ๐ซ๐š๐ฅ ๐ž-๐ฉ๐จ๐ฌ๐ญ๐ž๐ซ ๐ฉ๐ซ๐ž๐ฌ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง and ๐ŸŽ๐Ÿ‘ ๐š๐›๐ฌ๐ญ๐ซ๐š๐œ๐ญ ๐ฌ๐ฎ๐›๐ฆ๐ข๐ญ๐ญ๐ž๐ in conference.

โฆฟ I had participated in ๐Ÿ๐ŸŽ ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž๐ฌ, ๐ŸŽ๐Ÿ ๐š๐›๐ฌ๐ญ๐ซ๐š๐œ๐ญ ๐ฌ๐ฎ๐›๐ฆ๐ข๐ญ๐ญ๐ž๐ and ๐ŸŽ๐Ÿ ๐Ž๐ซ๐š๐ฅ ๐ฉ๐š๐ฉ๐ž๐ซ ๐ฉ๐ซ๐ž๐ฌ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง conducted by Eudoxia Research University, New Castle, USA.

โฆฟ I had attended and participated in ๐ŸŽ๐Ÿ— ๐…๐ƒ๐ ๐š๐ญ I๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐ฅ๐ž๐ฏ๐ž๐ฅ.

โฆฟ I had attended ๐ŸŽ๐Ÿ— ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ/๐๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐–๐จ๐ซ๐ค๐ฌ๐ก๐จ๐ฉ and ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐’๐ฒ๐ฆ๐ฉ๐จ๐ฌ๐ข๐ฎ๐ฆ ๐ŸŽ๐Ÿ as my achievement.

โฆฟ I had recently published ๐ŸŽ๐Ÿ• ๐“๐—ฒ๐˜…๐˜ ๐—•๐—ผ๐—ผ๐—ธ๐˜€ at D. Pharm, B. Pharm and M. Pharm level students [KDP, JEC Publishers and Pritam Publications]

โฆฟ I had recently published 01 ๐“๐—ฒ๐˜…๐˜ ๐—•๐—ผ๐—ผ๐—ธ๐˜€ [๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐š๐ซ ๐๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ] at M. Pharm level students with ๐๐• ๐๐ฎ๐›๐ฅ๐ข๐œ๐š๐ญ๐ข๐จ๐ง๐ฌ.

โฆฟ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต๐—š๐—ฎ๐˜๐—ฒ ๐—ฆ๐˜๐—ฎ๐˜๐˜€: I got ๐Ÿ,๐ŸŽ๐Ÿ“๐Ÿ‘+ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐ˆ๐ง๐ญ๐ž๐ซ๐ž๐ฌ๐ญ ๐’๐œ๐จ๐ซ๐ž๐ฌ, ๐Ÿ๐Ÿ•๐Ÿ‘,๐Ÿ’๐Ÿ๐Ÿ“+ ๐ซ๐ž๐š๐๐ฌ, ๐Ÿ๐Ÿ๐Ÿ• ๐‚๐ข๐ญ๐š๐ญ๐ข๐จ๐ง๐ฌ (๐ก-๐ข๐ง๐๐ž๐ฑ ๐Ÿ—) ๐š๐ง๐ ๐Ÿ“๐Ÿ–๐Ÿ–+ ๐ซ๐ž๐œ๐จ๐ฆ๐ฆ๐ž๐ง๐๐š๐ญ๐ข๐จ๐ง๐ฌ ๐จ๐ง ๐ฆ๐ฒ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก๐†๐š๐ญ๐ž ๐ฉ๐ซ๐จ๐Ÿ๐ข๐ฅ๐ž.

โฆฟ ๐—š๐—ผ๐—ผ๐—ด๐—น๐—ฒ ๐—ฆ๐—ฐ๐—ต๐—ผ๐—น๐—ฎ๐—ฟ ๐—ฆ๐˜๐—ฎ๐˜๐˜€: I had contributed with ๐Ÿ๐Ÿ—๐Ÿ ๐‚๐ข๐ญ๐š๐ญ๐ข๐จ๐ง, ๐ก-๐ข๐ง๐๐ž๐ฑ ๐Ÿ– ๐š๐ง๐ 4 ๐ข๐Ÿ๐ŸŽ-๐ข๐ง๐๐ž๐ฑ on it.

โฆฟ I'm ๐ซ๐ž๐ฏ๐ข๐ž๐ฐ๐ž๐ซ ๐›๐จ๐š๐ซ๐ ๐ฆ๐ž๐ฆ๐›๐ž๐ซ ๐จ๐Ÿ ๐ฆ๐จ๐ซ๐ž ๐ญ๐ก๐š๐ง 25 Google scholar and NLM based journals, and ๐ŸŽ๐Ÿ ๐–๐ž๐› ๐จ๐Ÿ ๐’๐œ๐ข๐ž๐ง๐œ๐ž ๐‰๐จ๐ฎ๐ซ๐ง๐š๐ฅ.

โฆฟ Providing Turnitin plag. report quickly for the Review, Research, Thesis and other related documents checking.

ะŸะพะปะฝะฐั ัั‚ะฐั‚ะธัั‚ะธะบะฐ
ะ’ัะตะณะพ ะฟัƒะฑะปะธะบะฐั†ะธะน
36
ะ’ัะตะณะพ ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน
96
ะฆะธั‚ะธั€ะพะฒะฐะฝะธะน ะฝะฐ ะฟัƒะฑะปะธะบะฐั†ะธัŽ
2.67
ะกั€ะตะดะฝะตะต ั‡ะธัะปะพ ะฟัƒะฑะปะธะบะฐั†ะธะน ะฒ ะณะพะด
9
ะกั€ะตะดะฝะตะต ั‡ะธัะปะพ ัะพะฐะฒั‚ะพั€ะพะฒ
4.47
ะ“ะพะดั‹ ะฟัƒะฑะปะธะบะฐั†ะธะน
2023-2026 (4 ะณะพะดะฐ)
h-index
5
i10-index
2
m-index
1.25
o-index
8
g-index
7
w-index
1
ะžะฟะธัะฐะฝะธะต ะผะตั‚ั€ะธะบ
h-index
ะฃั‡ั‘ะฝั‹ะน ะธะผะตะตั‚ ะธะฝะดะตะบั h, ะตัะปะธ h ะธะท ะตะณะพ N ัั‚ะฐั‚ะตะน ั†ะธั‚ะธั€ัƒัŽั‚ัั ะบะฐะบ ะผะธะฝะธะผัƒะผ h ั€ะฐะท ะบะฐะถะดะฐั, ะฒ ั‚ะพ ะฒั€ะตะผั ะบะฐะบ ะพัั‚ะฐะฒัˆะธะตัั (N - h) ัั‚ะฐั‚ะตะน ั†ะธั‚ะธั€ัƒัŽั‚ัั ะฝะต ะฑะพะปะตะต ั‡ะตะผ h ั€ะฐะท ะบะฐะถะดะฐั.
i10-index
ะงะธัะปะพ ัั‚ะฐั‚ะตะน ะฐะฒั‚ะพั€ะฐ, ะฟะพะปัƒั‡ะธะฒัˆะธั… ะฝะต ะผะตะฝะตะต 10 ััั‹ะปะพะบ ะบะฐะถะดะฐั.
m-index
m-ะธะฝะดะตะบั ัƒั‡ะตะฝะพะณะพ ั‡ะธัะปะตะฝะฝะพ ั€ะฐะฒะตะฝ ะพั‚ะฝะพัˆะตะฝะธัŽ ะตะณะพ h-ะธะฝะดะตะบัะฐ ะบ ะบะพะปะธั‡ะตัั‚ะฒัƒ ะปะตั‚, ะฟั€ะพัˆะตะดัˆะธั… ั ะผะพะผะตะฝั‚ะฐ ะฟะตั€ะฒะพะน ะฟัƒะฑะปะธะบะฐั†ะธะธ.
o-index
ะกั€ะตะดะฝะตะต ะณะตะพะผะตั‚ั€ะธั‡ะตัะบะพะต h-ะธะฝะดะตะบัะฐ ะธ ั‡ะธัะปะฐ ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน ะฝะฐะธะฑะพะปะตะต ั†ะธั‚ะธั€ัƒะตะผะพะน ัั‚ะฐั‚ัŒะธ ัƒั‡ะตะฝะพะณะพ.
g-index
ะ”ะปั ะดะฐะฝะฝะพะณะพ ะผะฝะพะถะตัั‚ะฒะฐ ัั‚ะฐั‚ะตะน, ะพั‚ัะพั€ั‚ะธั€ะพะฒะฐะฝะฝะพะณะพ ะฒ ะฟะพั€ัะดะบะต ัƒะฑั‹ะฒะฐะฝะธั ะบะพะปะธั‡ะตัั‚ะฒะฐ ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, ะบะพั‚ะพั€ั‹ะต ะฟะพะปัƒั‡ะธะปะธ ัั‚ะธ ัั‚ะฐั‚ัŒะธ, g-ะธะฝะดะตะบั ัั‚ะพ ะฝะฐะธะฑะพะปัŒัˆะตะต ั‡ะธัะปะพ, ั‚ะฐะบะพะต ั‡ั‚ะพ g ัะฐะผั‹ั… ั†ะธั‚ะธั€ัƒะตะผั‹ั… ัั‚ะฐั‚ะตะน ะฟะพะปัƒั‡ะธะปะธ (ััƒะผะผะฐั€ะฝะพ) ะฝะต ะผะตะฝะตะต g2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน.
w-index
ะ•ัะปะธ w ัั‚ะฐั‚ะตะน ัƒั‡ะตะฝะพะณะพ ะธะผะตัŽั‚ ะฝะต ะผะตะฝะตะต 10w ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน ะบะฐะถะดะฐั ะธ ะดั€ัƒะณะธะต ัั‚ะฐั‚ัŒะธ ะผะตะฝัŒัˆะต, ั‡ะตะผ 10(w+1) ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, ั‚ะพ w-ะธะฝะดะตะบั ะธััะปะตะดะพะฒะฐั‚ะตะปั ั€ะฐะฒะตะฝ w.

ะ–ัƒั€ะฝะฐะปั‹

1
2
3
4
5
Journal of Drug Delivery and Therapeutics
5 ะฟัƒะฑะปะธะบะฐั†ะธะน, 13.89%
Drug Delivery Letters
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Nanoscience and Nanotechnology - Asia
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Current Nanomedicine
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Advances in Research
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Recent Advances in Drug Delivery and Formulation
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Journal of Pharmacognosy and Phytochemistry
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
iScience
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Journal of Microencapsulation
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Pharmaceutical Nanotechnology
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Current Rheumatology Reviews
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Journal of Drug Delivery Science and Technology
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Current Aging Science
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Journal of Pharmaceutical Research International
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
International Journal of Pharmaceutical Investigation
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Journal of Advances in Medicine and Medical Research
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Asian Journal of Research in Computer Science
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
International Research Journal of Modernization in Engineering Technology and Science
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
International Journal of Pharmaceutical Sciences and Medicine
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
International Journal of Computing and Artificial Intelligence
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
1
2
3
4
5

ะฆะธั‚ะธั€ัƒัŽั‰ะธะต ะถัƒั€ะฝะฐะปั‹

1
2
3
4
5
ะ–ัƒั€ะฝะฐะป ะฝะต ะพะฟั€ะตะดะตะปั‘ะฝ, 5, 5.21%
ะ–ัƒั€ะฝะฐะป ะฝะต ะพะฟั€ะตะดะตะปั‘ะฝ
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 5.21%
Microbial Pathogenesis
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 4.17%
Journal of Drug Delivery and Therapeutics
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 4.17%
Asian Journal of Research in Computer Science
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 4.17%
Journal of Microencapsulation
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
Journal of Drug Delivery Science and Technology
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
Journal of Pharmaceutical Innovation
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
Phytomedicine Plus
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
Pharmaceutics
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
International Journal of Peptide Research and Therapeutics
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
International Journal of Nanomedicine
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
International Journal of Molecular Sciences
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
Physiological Mini Reviews
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ACS Applied Nano Materials
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Indian Journal of Dental Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Naunyn-Schmiedeberg's Archives of Pharmacology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Pharmaceutical Development and Technology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
BMC Cancer
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Journal of Pharmaceutical Sciences
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Nanomedicine: Nanotechnology, Biology, and Medicine
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Pathogens and Global Health
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ACS Nano
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Chemical Communications
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
European Journal of Pharmaceutical Sciences
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Macromolecular Materials and Engineering
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Expert Opinion on Drug Delivery
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
International Journal of Risk and Safety in Medicine
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Polymers
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Foods
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Journal of Nanobiotechnology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
AAPS PharmSciTech
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Fitoterapia
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Scientific Reports
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Fermentation
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Proceedings of the Institution of Mechanical Engineers, Part E: Journal of Process Mechanical Engineering
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Pharmaceutical Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Cosmetics
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Journal of Biomaterials Science, Polymer Edition
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Regenerative Engineering and Translational Medicine
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Acta Pharmaceutica
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Polymer-Plastics Technology and Materials
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Current Nutrition Reports
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Nano-Structures and Nano-Objects
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Langmuir
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Journal of Food Measurement and Characterization
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Advances in Natural Sciences: Nanoscience and Nanotechnology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Phytotherapy Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Polymers for Advanced Technologies
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Advanced healthcare materials
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Chemical Engineering Research and Design
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
International Journal of Biological Macromolecules
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Drug Discovery Today
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
3D Printing and Additive Manufacturing
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Polymer Bulletin
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Biomedicine and Pharmacotherapy
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Drug Development and Industrial Pharmacy
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
IEEE Access
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ACS Applied Polymer Materials
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Carbohydrate Polymer Technologies and Applications
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ACS Polymers Au
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Food Bioengineering
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Administrative Sciences
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Advances in Traditional Medicine
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
CABI Agriculture and Bioscience
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Discover Materials
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Network
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Applied Food Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Hybrid Advances
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Advances in Chemical Pollution, Environmental Management and Protection
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
Next Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
1
2
3
4
5

ะฆะธั‚ะธั€ัƒะตะผั‹ะต ะถัƒั€ะฝะฐะปั‹

5
10
15
20
25
30
35
40
45
ะ–ัƒั€ะฝะฐะป ะฝะต ะพะฟั€ะตะดะตะปั‘ะฝ, 43, 8.1%
ะ–ัƒั€ะฝะฐะป ะฝะต ะพะฟั€ะตะดะตะปั‘ะฝ
43 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 8.1%
International Journal of Nanomedicine
12 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 2.26%
International Journal of Pharmaceutics
11 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 2.07%
Pharmaceutics
11 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 2.07%
Journal of Controlled Release
11 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 2.07%
Journal of Drug Delivery Science and Technology
10 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.88%
Theranostics
9 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.69%
Advanced Drug Delivery Reviews
8 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.51%
Scientific Reports
8 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.51%
ACS applied materials & interfaces
6 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.13%
ACS Nano
6 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.13%
Nanomaterials
6 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.13%
Biomaterials
6 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 1.13%
Colloids and Surfaces B: Biointerfaces
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 0.94%
Clinical Cancer Research
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 0.94%
Cancer Research
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 0.94%
Journal of Nanobiotechnology
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 0.94%
Journal of Microencapsulation
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Nanomedicine: Nanotechnology, Biology, and Medicine
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Frontiers in Pharmacology
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Neuro-Oncology
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Journal of Biomedical Nanotechnology
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Molecular Pharmaceutics
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.75%
Proceedings of the National Academy of Sciences of the United States of America
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
World Neurosurgery
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Molecules
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Expert Opinion on Therapeutic Patents
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
European Journal of Medicinal Chemistry
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Frontiers in Bioengineering and Biotechnology
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Nature Methods
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
International Journal of Molecular Sciences
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Tuberculosis
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Nature Biotechnology
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Angewandte Chemie - International Edition
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Nature Medicine
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Journal of Neurosurgery
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Biomedicine and Pharmacotherapy
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Advanced Materials
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Advanced Therapeutics
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
Journal of Drug Delivery and Therapeutics
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.56%
International Journal of Infectious Diseases
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nanoscale
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Journal of Nuclear Medicine
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Indian Journal of Tuberculosis
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Pharmaceutical Development and Technology
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Stem Cell Research and Therapy
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Molecular Imaging and Biology
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Oncotarget
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
European Journal of Pharmaceutical Sciences
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Small
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Journal of Neuro-Oncology
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nano Letters
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Polymers
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Journal of Biomedical Optics
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nature Reviews Drug Discovery
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Journal of Liposome Research
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Pharmaceutical Research
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Antimicrobial Agents and Chemotherapy
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nature Chemical Biology
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Heliyon
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nanomedicine
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Annals of the Rheumatic Diseases
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nanoscience and Nanotechnology - Asia
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Breathe
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
PLoS ONE
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Progress in Biomaterials
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Emerging Topics in Life Sciences
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 0.38%
Nature Nanotechnology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Science Translational Medicine
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Drugs
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
The Lancet Oncology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
European Journal of Nuclear Medicine and Molecular Imaging
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Cancer Investigation
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Optics Letters
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Journal of Food Processing and Preservation
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Lecture Notes in Computer Science
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Micromachines
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Pharmaceuticals
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Materials Today Chemistry
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Journal of Clinical Investigation
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Nano Today
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Antibiotics
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Accounts of Chemical Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Cancer Letters
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Frontiers in Immunology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Current Opinion in Infectious Diseases
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Journal of Industrial and Engineering Chemistry
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Trends in Food Science and Technology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Advances in Therapy
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Journal of Multidisciplinary Healthcare
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Molecular Biology Reports
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
NeuroToxicology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
RSC Advances
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Current Topics in Medicinal Chemistry
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Annals of Oncology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Methods in Molecular Biology
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Expert Review of Neurotherapeutics
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Chemical Biology and Drug Design
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Brain Sciences
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
Tropical Journal of Pharmaceutical Research
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 0.19%
5
10
15
20
25
30
35
40
45

ะ˜ะทะดะฐั‚ะตะปะธ

2
4
6
8
10
12
Bentham Science Publishers Ltd.
11 ะฟัƒะฑะปะธะบะฐั†ะธะน, 30.56%
Sciencedomain International
5 ะฟัƒะฑะปะธะบะฐั†ะธะน, 13.89%
Society of Pharmaceutical Tecnocrats
5 ะฟัƒะฑะปะธะบะฐั†ะธะน, 13.89%
Elsevier
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
AkiNik Publications
2 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 5.56%
Taylor & Francis
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
MANUSCRIPT TECHNOMEDIA LLP
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Comprehensive Publications
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
Zain Publications
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
International Research Journal of Modernization in Engineering Technology and Science
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
2
4
6
8
10
12

ะžั€ะณะฐะฝะธะทะฐั†ะธะธ ะธะท ะฟัƒะฑะปะธะบะฐั†ะธะน

5
10
15
20
25
ะžั€ะณะฐะฝะธะทะฐั†ะธั ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ, 22, 61.11%
ะžั€ะณะฐะฝะธะทะฐั†ะธั ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ
22 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 61.11%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ะฐ ะงะธั‚ะบะฐั€ะฐ
7 ะฟัƒะฑะปะธะบะฐั†ะธะน, 19.44%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะ ะฐะดะถะฐัั‚ะฐะฝะฐ
4 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 11.11%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะะ˜ะœะก
4 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 11.11%
ะŸะตะฝะดะถะฐะฑัะบะธะน ั‚ะตั…ะฝะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะ˜. ะš. ะ“ัƒะดะถั€ะฐะปะฐ
3 ะฟัƒะฑะปะธะบะฐั†ะธะธ, 8.33%
ะ”ะถะฐะผะธั ะฅะฐะผะดะฐั€ะด
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
JSS ะะบะฐะดะตะผะธั ะฒั‹ััˆะตะณะพ ะพะฑั€ะฐะทะพะฒะฐะฝะธั ะธ ะธััะปะตะดะพะฒะฐะฝะธะน
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะœะฐั…ะฐั€ะธัˆะธ ะœะฐั€ะบะฐะฝะดะตัˆะฒะฐั€ะฐ, ะœัƒะปะปะฐะฝะฐ
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
ะœะฐััะฐั‡ัƒัะตั‚ัะบะฐั ะฑะพะปัŒะฝะธั†ะฐ ะพะฑั‰ะตะณะพ ะฟั€ะพั„ะธะปั
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
ะœะตะดะธั†ะธะฝัะบะฐั ัˆะบะพะปะฐ ะธะผะตะฝะธ ะงะฐะฝะฐ ะฟั€ะธ ะœะฐััะฐั‡ัƒัะตั‚ัะบะพะผ ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ะต
1 ะฟัƒะฑะปะธะบะฐั†ะธั, 2.78%
5
10
15
20
25

ะกั‚ั€ะฐะฝั‹ ะธะท ะฟัƒะฑะปะธะบะฐั†ะธะน

5
10
15
20
25
30
ะกั‚ั€ะฐะฝะฐ ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ, 28, 77.78%
ะกั‚ั€ะฐะฝะฐ ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ
28 ะฟัƒะฑะปะธะบะฐั†ะธะน, 77.78%
ะ˜ะฝะดะธั, 13, 36.11%
ะ˜ะฝะดะธั
13 ะฟัƒะฑะปะธะบะฐั†ะธะน, 36.11%
ะกะจะ, 5, 13.89%
ะกะจะ
5 ะฟัƒะฑะปะธะบะฐั†ะธะน, 13.89%
5
10
15
20
25
30

ะฆะธั‚ะธั€ัƒัŽั‰ะธะต ะพั€ะณะฐะฝะธะทะฐั†ะธะธ

5
10
15
20
25
30
35
ะžั€ะณะฐะฝะธะทะฐั†ะธั ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ, 35, 36.46%
ะžั€ะณะฐะฝะธะทะฐั†ะธั ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ
35 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 36.46%
ะกะฐะฒะตั‚ัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะผะตะดะธั†ะธะฝัะบะธั… ะธ ั‚ะตั…ะฝะธั‡ะตัะบะธั… ะฝะฐัƒะบ
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะœะฐะปะฐะนั
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ะงะธะฐะฝะณะผะฐะนัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะบะพั€ะพะปั ะกะฐัƒะดะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะบะพั€ะพะปั ะฅะฐะปะธะดะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะฟั€ะธะฝั†ะตััั‹ ะัƒั€ั‹ ะ‘ะธะฝั‚ ะะฑะดัƒะป ะ ะฐั…ะผะฐะฝ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะฅะฐะดะถะตั‚ั‚ะตะฟะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸั€ะธะฝั†ะฐ ะกะฐั‚ั‚ะฐะผะฐ ะฑะธะฝ ะะฑะดัƒะปะฐะทะธะทะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะญะปัŒ-ะะนะฝะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ะฝะดะธะนัะบะธะน ะฝะฐัƒั‡ะฝั‹ะน ะธะฝัั‚ะธั‚ัƒั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะขะตะฑั€ะธะทัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ’ะตะปะปะพั€ัะบะธะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะขะตั…ะฝะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะ™ั‹ะปะดั‹ะท
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะœะฐะปะฐะบะฐะฝะดะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะœะตะถะดัƒะฝะฐั€ะพะดะฝั‹ะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะ ะธั„ะฐั…ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ะฝะดะธะนัะบะธะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะฒ ะœะฐะดั€ะฐัะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸัƒะฝั‹
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฐั†ะธะพะฝะฐะปัŒะฝั‹ะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะฒ ะ’ะฐั€ะฐะฝะณะฐะปะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฐั†ะธะพะฝะฐะปัŒะฝั‹ะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะฒ ะœะตะณั…ะฐะปะฐะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ัะปะฐะผัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะะทะฐะด, ะขะตะณะตั€ะฐะฝ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะšะฐั€ะฐั‡ะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะ“ะพะผะฐะป
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะญั€ะฐะบัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ั‚ะตั…ะฝะพะปะพะณะธะน
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะกะฒะฐะฑะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะบะฐะดะตะผะธั ะธัะบัƒััั‚ะฒ, ะฝะฐัƒะบะธ, ั‚ะตั…ะฝะพะปะพะณะธะน ะธ ะธััะปะตะดะพะฒะฐะฝะธะน ะจะฐะฝะผัƒะณะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะะปัŒะทะฐั…ั€ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะงะถัั†ะทัะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ‘ั…ะฐั€ะฐั‚ัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะฒั‹ััˆะตะณะพ ะพะฑั€ะฐะทะพะฒะฐะฝะธั ะธ ะธััะปะตะดะพะฒะฐะฝะธะน
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะ ะฐะดะถะฐัั‚ะฐะฝะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะœัƒัั‚ะฐั„ั‹ ะšะตะผะฐะปั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸัƒั‚ั€ะฐ ะฒ ะœะฐะปะฐะนะทะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะขะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะœะะ ะ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะขะธั€ั‚ั…ะฐะฝะบะตั€ะฐ ะœะฐั…ะฐะฒะธั€ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ’ะตะป ะขะตั… ะ ะฐะฝะณะฐั€ะฐะดะถะฐะฝ ะะฐัƒั‡ะฝะพ-ะธััะปะตะดะพะฒะฐั‚ะตะปัŒัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚ ะฝะฐัƒะบะธ ะธ ั‚ะตั…ะฝะพะปะพะณะธะน ะดะพะบั‚ะพั€ะฐ ะกะฐะณัƒะฝั‚ะฐะปั‹
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะจะฐั€ะดะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ USCI
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะพะปะปะตะดะถ ะ›ะธะฝะบะพะปัŒะฝัะบะพะณะพ ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ะฐ ะฒ ะšัƒะฐะปะฐ-ะ›ัƒะผะฟัƒั€ะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃั…ะฐะฝัŒัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะตะฐะฟะพะปะธั‚ะฐะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะธะผะตะฝะธ ะคั€ะธะดั€ะธั…ะฐ II
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะธั‚ะฐะนัะบะธะน ัะตะปัŒัะบะพั…ะพะทัะนัั‚ะฒะตะฝะฝั‹ะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะœะธะปะฐะฝัะบะธะน ั‚ะตั…ะฝะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฐัƒั‡ะฝั‹ะต ะธะฝัั‚ะธั‚ัƒั‚ั‹ ะณะพัะฟะธั‚ะฐะปะธะทะฐั†ะธะธ ะธ ะปะตั‡ะตะฝะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะœะธะปะฐะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะะ˜ะœะก
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸะฐะปะตั€ะผะพ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะŸะฐะดัƒะฐะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะฆะทัะฝััƒ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฎะณะพ-ะทะฐะฟะฐะดะฝั‹ะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะฆะทัะพั‚ัƒะฝ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฝัŒั…ะพะนัะบะธะน ะผะตะดะธั†ะธะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะคะปะพั€ะตะฝั†ะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ ะธะผัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะขะพั€ ะ’ะตั€ะณะฐั‚ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะฐะธั€ัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฐั†ะธะพะฝะฐะปัŒะฝั‹ะน ะผะตะถัƒะฝะธะฒะตั€ัะธั‚ะตั‚ัะบะธะน ะบะพะฝัะพั€ั†ะธัƒะผ ั‚ะตะปะตะบะพะผะผัƒะฝะธะบะฐั†ะธะน
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ‘ะพะปัŒะฝะธั†ะฐ ะคะพะฝะดะฐ ะกะฐะฝั‚ะฐ-ะ›ัŽัะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะกะฐััะฐั€ะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะฐะผะฟัƒั ะฑะธะพะผะตะดะธั†ะธะฝัะบะพะณะพ ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะŸะพะปะธะบะปะธะฝะธะบะฐ ะขะพั€ ะ’ะตั€ะณะฐั‚ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะžะบะปะตะฝะดัะบะธะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ะฐ ะงะธั‚ะบะฐั€ะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะกะฐะฝัˆะฐะนะฝ-ะšะพัั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸั€ะตั‚ะพั€ะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะŸะฐะดะถะฐะดะถะฐั€ะฐะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะงัƒะปะฐะปะพะฝะณะบะพั€ะฝะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะœะฐะต ะคะฐ ะ›ัƒะฐะฝะณ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะšะปะตะผัะพะฝะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ“ะพะฝะบะพะฝะณัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะขะตั…ะฐััะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะฒ ะžัั‚ะธะฝะต
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะŸะตั€ะดัŒัŽ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะงะตะฝะฝะฐะนัะบะธะน ั‚ะตั…ะฝะพะปะพะณะธั‡ะตัะบะธะน ะธะฝัั‚ะธั‚ัƒั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะะนะฝ-ะจะฐะผั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะ›ะธะฝะบะพะปัŒะฝะฐ (ะŸะตะฝัะธะปัŒะฒะฐะฝะธั)
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ’ะฐะปะตะฝัะธะนัะบะธะน ะœะตะถะดัƒะฝะฐั€ะพะดะฝั‹ะน ะฃะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะœะตะถะดัƒะฝะฐั€ะพะดะฝั‹ะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะ›ะฐ-ะ ะธะพั…ะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ 6-ะณะพ ะžะบั‚ัะฑั€ั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะฐะฝะฐะดัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะั…ั€ะฐะผะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะผะตะดะธั†ะธะฝั‹ ะธ ั„ะฐั€ะผะฐั†ะธะธ ะธะผ. ะšัั€ะพะป ะ”ะฐะฒะธะปะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ‘ัƒั…ะฐั€ะตัั‚ัะบะธะน ะฟะพะปะธั‚ะตั…ะฝะธั‡ะตัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ›ะธะผะตั€ะธะบัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะœะตะดะธั†ะธะฝัะบะธะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะกะธะปะตะทะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะฏะฝะฐ ะ”ะปัƒะณะพัˆะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะฐั†ะธะพะฝะฐะปัŒะฝั‹ะน ัƒะฝะธะฒะตั€ัะธั‚ะตั‚ ะšะพะปัƒะผะฑะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะะฝั‚ะธะพะบะธะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะฝะธะฒะตั€ัะธั‚ะตั‚ ะกะฐะฝั‚ัŒัะณะพ ะดะต ะšะฐะปะธ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฆะตะฝั‚ั€ ะฟะพะปะธะผะตั€ะฝั‹ั… ะธ ัƒะณะปะตั€ะพะดะฝั‹ั… ะผะฐั‚ะตั€ะธะฐะปะพะฒ, ะŸะพะปัŒัะบะฐั ะฐะบะฐะดะตะผะธั ะฝะฐัƒะบ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
5
10
15
20
25
30
35

ะฆะธั‚ะธั€ัƒัŽั‰ะธะต ัั‚ั€ะฐะฝั‹

5
10
15
20
25
30
35
ะกั‚ั€ะฐะฝะฐ ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ, 35, 36.46%
ะกั‚ั€ะฐะฝะฐ ะฝะต ะพะฟั€ะตะดะตะปะตะฝะฐ
35 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 36.46%
ะ˜ะฝะดะธั, 23, 23.96%
ะ˜ะฝะดะธั
23 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 23.96%
ะšะธั‚ะฐะน, 6, 6.25%
ะšะธั‚ะฐะน
6 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 6.25%
ะ˜ั‚ะฐะปะธั, 5, 5.21%
ะ˜ั‚ะฐะปะธั
5 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะน, 5.21%
ะกะจะ, 4, 4.17%
ะกะจะ
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 4.17%
ะขะฐะธะปะฐะฝะด, 4, 4.17%
ะขะฐะธะปะฐะฝะด
4 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 4.17%
ะœะฐะปะฐะนะทะธั, 3, 3.13%
ะœะฐะปะฐะนะทะธั
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
ะŸะฐะบะธัั‚ะฐะฝ, 3, 3.13%
ะŸะฐะบะธัั‚ะฐะฝ
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
ะขัƒั€ั†ะธั, 3, 3.13%
ะขัƒั€ั†ะธั
3 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 3.13%
ะ•ะณะธะฟะตั‚, 2, 2.08%
ะ•ะณะธะฟะตั‚
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ะ˜ั€ะฐะฝ, 2, 2.08%
ะ˜ั€ะฐะฝ
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ะกะฐัƒะดะพะฒัะบะฐั ะั€ะฐะฒะธั, 2, 2.08%
ะกะฐัƒะดะพะฒัะบะฐั ะั€ะฐะฒะธั
2 ั†ะธั‚ะธั€ะพะฒะฐะฝะธั, 2.08%
ะะฒัั‚ั€ะฐะปะธั, 1, 1.04%
ะะฒัั‚ั€ะฐะปะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ“ะฐะฝะฐ, 1, 1.04%
ะ“ะฐะฝะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ“ะพะฝะบะพะฝะณ (ะกะะ ), 1, 1.04%
ะ“ะพะฝะบะพะฝะณ (ะกะะ )
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ะฝะดะพะฝะตะทะธั, 1, 1.04%
ะ˜ะฝะดะพะฝะตะทะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ั€ะฐะบ, 1, 1.04%
ะ˜ั€ะฐะบ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ั€ะปะฐะฝะดะธั, 1, 1.04%
ะ˜ั€ะปะฐะฝะดะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ˜ัะฟะฐะฝะธั, 1, 1.04%
ะ˜ัะฟะฐะฝะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะšะพะปัƒะผะฑะธั, 1, 1.04%
ะšะพะปัƒะผะฑะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะะพะฒะฐั ะ—ะตะปะฐะฝะดะธั, 1, 1.04%
ะะพะฒะฐั ะ—ะตะปะฐะฝะดะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะžะะญ, 1, 1.04%
ะžะะญ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะŸะพะปัŒัˆะฐ, 1, 1.04%
ะŸะพะปัŒัˆะฐ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ ะตัะฟัƒะฑะปะธะบะฐ ะšะพั€ะตั, 1, 1.04%
ะ ะตัะฟัƒะฑะปะธะบะฐ ะšะพั€ะตั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะ ัƒะผั‹ะฝะธั, 1, 1.04%
ะ ัƒะผั‹ะฝะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฃะทะฑะตะบะธัั‚ะฐะฝ, 1, 1.04%
ะฃะทะฑะตะบะธัั‚ะฐะฝ
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะญั„ะธะพะฟะธั, 1, 1.04%
ะญั„ะธะพะฟะธั
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
ะฎะะ , 1, 1.04%
ะฎะะ 
1 ั†ะธั‚ะธั€ะพะฒะฐะฝะธะต, 1.04%
5
10
15
20
25
30
35
  • ะœั‹ ะฝะต ัƒั‡ะธั‚ั‹ะฒะฐะตะผ ะฟัƒะฑะปะธะบะฐั†ะธะธ, ัƒ ะบะพั‚ะพั€ั‹ั… ะฝะตั‚ DOI.
  • ะกั‚ะฐั‚ะธัั‚ะธะบะฐ ะฟะตั€ะตัั‡ะธั‚ั‹ะฒะฐะตั‚ัั ั€ะฐะท ะฒ ััƒั‚ะบะธ.